RE:RE:RE:RE:Annual meeting I think you know that I'm most bothered about the confusion around the NASH program, I think we are all concerned about that. I see that confusion as not coming from bad messaging but from the fact the program is ACTUALLY confusing for a number of reasons. A letter to proceed should be a clear solid step forward, it really should follow with the company clarifying how they will proceed. But like with many other things in THTX's NASH program this solid step forward is wrapped in confusion because they havent clearly stated how they will proceed. So rather than being the solid step forward it has actually reconfirmed the confusing nature of this program. In this specific case what the letter may proceed means to me is things are out of the hands of the fda and in the hands of the company because I don't understand how the fda can walk back from this position so that's a positive. But the fact the company hasn't clarified the situation is worrying, not fatal just keeps things uncertain or maybe speculative is a better word. I just don't believe the company are too inept to explain this clearly so I have to believe there just isn't a clear explanation atm. It's agonizing to say but after all this time we are still in wait and see mode.
Btw none of this is intended to contradict SPCEO's point that given the circumstances the company have made the absolute most out of what they have.
Bucknelly21 wrote: I'm curious does getting the fda letter to proceed for phase 3 and the market not even sniffing at it the same kind of irrational market behavior you are referring too?